Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05121662 · ClinicalTrials.gov registry record
COVID-19 Vaccine Biomarker Study in Multiple Sclerosis
A clinical trial, sponsored by Columbia University.
- Completed
- Registry status
- 154
- Enrollment target
NCT05121662: Completed study, sponsored by Columbia University.
NCT05121662 is a clinical trial that has completed, run by Columbia University. The registered enrollment target is 154 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05121662 has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 154 participants
- Enrollment target
Study Summary
SARS CoV-2 is the virus responsible for the pandemic COVID-19, which has resulted in nearly five million deaths worldwide since its spread in the beginning of 2020. In the United States, there are now two emergency use authorized vaccines that make use of messenger ribonucleic acid (mRNA) based technology that are highly effective for preventing COVID. However, because multiple sclerosis is an autoimmune condition, many individuals with multiple sclerosis take medicines that affect the immune system. The investigators are not sure whether individuals on certain MS medications, including medications that lower a type of immune cell called B lymphocytes, will form as robust of a response to the vaccines. In this study, the investigators will be gathering more information about effectiveness of these vaccines and bloodwork that looks at antibodies and other markers of vaccine response and by asking patients about COVID-19 infections.
Primary Outcome
Level of RBD binding Immunoglobulin G (IgG) in blood samples
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2021-07-29 |
| Est. Completion | 2025-02-13 |
What the finished NCT05121662 record still lists
NCT05121662 is an observational study that tracks outcomes without assigning an intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05121662 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05121662 about?
NCT05121662 is a clinical study titled "COVID-19 Vaccine Biomarker Study in Multiple Sclerosis". SARS CoV-2 is the virus responsible for the pandemic COVID-19, which has resulted in nearly five million deaths worldwide since its spread in the beginning of 2020. In the United States, there are now two emergency use authorized vaccines that make use of messenger ribonucleic acid (mRNA) based tech...
What is the current status of trial NCT05121662?
This trial is currently completed. The enrollment target is 154 participants. The study started on 2021-07-29. Estimated completion is 2025-02-13.
Who is sponsoring clinical trial NCT05121662?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04300998 · 154 participants
Study of CAR-T Therapy in Older Patients
- NCT04597372 · 154 participants · Phase 2
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
- NCT05294042 · 154 participants · NA
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
- NCT05512390 · 154 participants · Phase 1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI